In a double-blind RCT, 50 mg CBD enhanced the acute pain-relieving effects of hydromorphone without increasing adverse effects, while 200 mg CBD increased both pain relief and bad effects.
Pain management clinicians, anesthesiologists, opioid prescribers, CBD researchers
50 mg CBD enhanced opioid analgesia without adding side effects
What the researchers found
When combined with hydromorphone (which alone did not reliably produce analgesia), CBD increased analgesic effects for some acute pain measures but not chronic pain models. At 50 mg, CBD enhanced analgesia without additional adverse effects. At 200 mg, there were concurrent increases in self-reported "bad effects." CBD also mitigated the psychomotor impairment caused by hydromorphone alone.
Why it matters
If low-dose CBD can enhance opioid analgesia, patients might need lower opioid doses, reducing addiction risk. The finding that CBD also reduced opioid-related psychomotor impairment adds a potential safety benefit.
The numbers in context
31 participants. 5 drug conditions. Hydromorphone 4mg + CBD 0, 50, 100, or 200mg. 50mg CBD enhanced acute analgesia without bad effects. 200mg CBD increased both analgesia and bad effects. CBD mitigated hydromorphone-induced psychomotor impairment.
How the study worked
Within-subjects, double-blind, double-dummy, randomized human laboratory trial with 31 healthy participants. Five conditions: placebo+placebo, hydromorphone+placebo, hydromorphone+50mg CBD, hydromorphone+100mg CBD, hydromorphone+200mg CBD. Quantitative sensory testing, subjective drug effects, and psychomotor assessments at multiple time points.
What this study cannot tell us
Small sample (n=31) of healthy volunteers, not chronic pain patients. Laboratory pain models may not reflect clinical pain. Single-dose design. Effects of repeated dosing are unknown.
How to read the evidence
Strong: randomized, double-blind, placebo-controlled, within-subjects design with multiple dose levels, though small sample of healthy volunteers
When this study was published
Published in 2025
The bigger picture
The opioid crisis has created urgent demand for opioid-sparing strategies. Low-dose CBD enhancing opioid analgesia while reducing psychomotor impairment is a promising combination that warrants larger clinical trials.
Questions still open
- Would these results translate to chronic pain patients? What is the optimal CBD dose for opioid-sparing effects? Would this approach work with other opioids?
Common questions
Can CBD replace opioids for pain?
Why did higher CBD doses cause problems?
Read the original research
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model.
Pain, 166(9), e175-e184
Citation
Bergeria, Cecilia L; Mun, Chung Jung; Speed, Traci J; Huhn, Andrew S; Wolinsky, David; Vandrey, Ryan; Campbell, Claudia M; Dunn, Kelly E. (2025). A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model.. Pain, 166(9), e175-e184. https://doi.org/10.1097/j.pain.0000000000003561
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk